Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine
Autor: | Yuki Imaoka, Yuusuke Sumi, Fumito Kuranishi, Yoji Uemae, Tadao Ohno, Hiroko Yasuda-Kurihara, Tsubasa Miyazaki, Takeshi Ishihara |
---|---|
Rok vydání: | 2018 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty Article Subject Population lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Clinical complete response Breast cancer Internal medicine Medicine Pharmacology (medical) education education.field_of_study business.industry Bone metastasis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Metastatic breast cancer Clinical trial 030220 oncology & carcinogenesis Cohort Clinical Study business 030217 neurology & neurosurgery Cohort study |
Zdroj: | International Journal of Breast Cancer International Journal of Breast Cancer, Vol 2018 (2018) |
ISSN: | 2090-3189 2090-3170 |
Popis: | Introduction. No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV). Patients and Methods. AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues. Results. Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988–2002) and in the nationwide population-based cohort study of Denmark (1999–2007). Conclusion. Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |